This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Watson Receives FTC Clearance For Actavis Acquisition

PARSIPPANY, N.J., Oct. 15, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that the Federal Trade Commission (FTC) has voted to approve Watson's acquisition of the Actavis group of companies.  The unanimous vote in support of the transaction follows Watson's agreement to a proposed consent order, pursuant to which Watson has agreed to divest certain products as a condition to obtaining FTC approval.  The parties have now obtained all regulatory approvals required to close the transaction.  Accordingly, the parties expect to consummate the acquisition in late October or early November.

Under the terms of the consent order with the FTC, Watson and Actavis have agreed to divest a number of marketed and pipeline products to Par Pharmaceutical Companies, Inc. and Sandoz.

Subject to the consummation of the transaction between Watson and Actavis, Par will acquire the following products:

  • Watson's Morphine Sulfate Extended Release Capsules
  • Actavis' Nifedipine Extended Release Tablets
  • Actavis' Metoclopramide Hydrochloride Tablets
  • Actavis' Fentanyl Transdermal Film
  • Actavis' Diltiazem Hydrochloride Extended Release Capsules

 

  • Watson's pending application for Adapalene/Benzoyl Peroxide Gel
  • Watson's pending application for Oxymorphone hydrochloride ER Tablets
  • Watson's pending application for Amphetamine Salts ER Tablets
  • Actavis' pending application for Rivastigmine Patch
  • Actavis' pending application for Glipizide Extended Release Tablets
  • Actavis' pending application for Varenicline Tartrate Tablets
  • Actavis' pending application for Oxycodone Hydrochloride Extended Release Tablets
  • Actavis' pending application for Ursodiol Tablets

 

  • Actavis' development stage Methylphenidate Hydrochloride Extended Release Tablets

Subject to the consummation of the transaction between Watson and Actavis, Sandoz will acquire the following products:

  • Actavis' Bupropion Hydrochloride 150 mg. Extended Release Tablets
  • Actavis' Lorazepam Tablets
  • Actavis' Diltiazem Hydrochloride Extended Release Capsules
  • Watson's pending application for Dextromethorphan Hydrobromide /Quinidine Sulfate




1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
SYM TRADE IT LAST %CHG

Markets

DOW 17,841.98 -86.22 -0.48%
S&P 500 2,080.15 -9.31 -0.45%
NASDAQ 4,919.6440 -19.6830 -0.40%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs